Synapse - Andrew Seidman

Search Within

Andrew D Seidman

Results (318)

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer

Journal Article

Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
Clinical Breast Cancer (2010)

Fulltext@MSK | Save

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer

Journal Article

Conlin, A.; Seidman, A.; Bach, A.; Lake, D.; Dickler, M.; D'Andrea, G.; Traina, T.; Danso, M.; Brufsky, A.; Saleh, M.; more...
Clinical Breast Cancer (2010)

Fulltext@MSK | Save

Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC)

Meeting Abstract

Seidman, A. D.; Brufsky, A.; Ansari, R. H.; Rubinsak, J. R.; Stein, R. S.; Schwartzberg, L. S.; Stewart, J. F.; Zhao, L.; Gill, J.; Tai, D.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer

Meeting Abstract

Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)

Meeting Abstract

Conlin, A. K.; Hudis, C. A.; Bach, A.; Moynahan, M.; Lake, D.; Forero-Torres, A.; Wright, G.; Hackney, M.; Clawson, A.; Seidman, A. D.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Uniformly positive (> 80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840

Meeting Abstract

Rimm, D. L.; Broadwater, G.; Friedman, P.; Berry, D.; Seidman, A.; Hudis, C.; Winer, E.; Harris, L.; Thor, A.
Cancer Research (2009)

Fulltext@MSK | Save

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results

Meeting Abstract

Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
Cancer Research (2009)

Fulltext@MSK | Save

Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes

Journal Article

Murphy, C. G.; Seidman, A. D.
Clinical Breast Cancer (2009)

Fulltext@MSK | Save

Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer

Journal Article

Kalinsky, K.; Ho, A.; Barker, C. A.; Seidman, A.
Current Breast Cancer Reports (2009)

Fulltext@MSK | Save

A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: Immunological effects

Journal Article

Deng, G.; Lin, H.; Seidman, A.; Fornier, M.; D'Andrea, G.; Wesa, K.; Yeung, S.; Cunningham Rundles, S.; Vickers, A. J.; Cassileth, B.
Journal of Cancer Research and Clinical Oncology (2009)

Fulltext@MSK | Save